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Introduction
This adoption resource has been compiled by the NICE adoption and impact team working with
Roche Diagnostics Limited for the Accelerated Access Collaborative (AAC). It has been developed
to provide practical information and advice to sites (NHS organisations) on adopting high-
sensitivity troponin tests with early rule-out protocols. These would help to rule out
non-ST-segment-elevation myocardial infarction (NSTEMI) quickly in people presenting to an
emergency department with chest pain suspected to be caused by acute coronary syndrome.
The AAC is a unique partnership bringing together leaders from across the healthcare landscape.
This includes government, NHS, industry and patient representatives. The AAC aims to drive the
uptake and adoption of innovation within the health and care system by identifying and supporting
the best new innovations that will be most promising for patients.
The AAC is supporting the rapid uptake of 7 high-potential technology areas with full evidence
bases already within the system. These products will enable patients to access new treatments
faster and improve patients' lives but are not currently available to everyone who could benefit.
One of the technology areas selected is high-sensitivity cardiac troponin testing for early rule out
of NSTEMI. This adoption resource forms part of the overall AAC implementation toolkit for this
workstream.
The information in this document is based on the experiences of healthcare professionals working
in 5 trusts in England and input from the National External Quality Assurance Service cardiac
markers scheme.
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Key points
In 2017–18 cardiac conditions were responsible for over half a million emergency department
attendances per year in England. There are around 75,000 emergency admissions annually for
heart attack.
Cardiac troponin I and cardiac troponin T are biological markers that are released into the
circulation when cardiac muscle is damaged. Troponins I and T are the recommended biomarkers
for diagnosing myocardial infarction in NICE's guideline on chest pain of recent onset. It can take up
to 12 hours after a heart attack for troponin levels to rise significantly.
Using non-high-sensitivity versions of the troponin assays can mean a prolonged stay in hospital
and multiple blood tests to safely rule out non-ST-segment-elevation myocardial infarction
(NSTEMI). High-sensitivity troponin assays were developed to detect troponin in the blood at
lower levels than non-high-sensitivity troponin assays. Using the high-sensitivity assays as part of
an early rule-out protocol can reduce time to discharge.
NICE's diagnostics guidance on early rule out of myocardial infarction recommends 2 high-
sensitivity troponin assays as options for the early rule out of NSTEMI in people presenting to an
emergency department with chest pain and suspected acute coronary syndrome.
The assays are recommended for use with early rule-out protocols. The protocols typically include
taking a blood sample for cardiac troponin I or T at initial assessment in an emergency department
and taking a second blood sample after 3 hours. Laboratories should report absolute values and the
upper reference limit should be set at the 99th percentile. Results should be interpreted along with
clinical judgement and the results of clinical assessment. Healthcare professionals should take into
account:
the pre-test probability of NSTEMI
the length of time since the suspected acute coronary syndrome
the possibility of chronically elevated troponin levels in some people and
that 99th percentile thresholds for troponin I and T may differ between sexes.
When NSTEMI is not excluded using an early rule-out protocol, further clinical assessment is
needed to determine whether a diagnosis of NSTEMI is appropriate.
NICE's guideline on chest pain of recent onset includes the diagnostics guidance recommendations.
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It also recommends that, for people at low risk of myocardial infarction, if the result of the high-
sensitivity troponin test taken at initial assessment is below the lower limit of detection, a single
test may only be required to rule out NSTEMI.
The 2015 European Society of Cardiology guidelines on the management of acute coronary
syndromes take the time since pain onset into account. They note that the 0 h/1 h algorithm (0 h
and 1 h refer to the time in hours from the first blood test) is an alternative to 0 h/3 h when high-
sensitivity cardiac troponin assays with a validated algorithm are available and that the cut-off
levels within the 0 h/1 h algorithm are assay specific.
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Overview of the implementation process
Adoption will take a tailored approach based on the local context of the site. Below is a suggested
outline process for adopting high-sensitivity troponin testing for early rule out of
non-ST-segment-elevation myocardial infarction (NSTEMI), which has been developed based on
the experience of healthcare professionals contributing to this adoption resource.
Figure 1 Outline implementation process for high-sensitivity troponin testing
Step 1: Stakeholder engagement
Establish a project team
A local project team will be able to work together to develop the implementation process and
manage the changes to practice needed. This could be an established chest pain working group with
experience in implementing other pathways and protocols or a newly formed group.
Identify the project leads:
A clinical project champion. Someone with an interest and enthusiasm to learn more about
using high-sensitivity troponin assays for early rule out of NSTEMI and who is familiar with the
relevant guidance and evidence.
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Project lead or manager who will be accountable for delivery.
Project or management sponsor who will be able to help assess the financial viability of the
project, ensure a business case is produced and help to show the potential cost savings.
Project team members are likely to include:
cardiologists
chest pain nurse specialists
emergency department doctors and senior nurses
clinical biochemists
doctors from the acute medical team.
Wider engagement of stakeholders
In addition to the stakeholder groups already represented on the local project team, engagement
and agreement on the planned changes should be sought from:
clinical directors
healthcare professionals working in the emergency department, acute medical units,
cardiology and hospital laboratories
directorate operational and finance management
pharmacists
commissioners.
Use for example: meetings, presentations and sharing copies of protocols, to secure support by
communicating the benefits and reasons for adoption.
Step 2: Assessment of readiness
Questions the project team should consider when building the case for adoption and developing
the implementation process are:
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Current demand
How many people present to the emergency department with chest pain suspected to be
caused by an acute coronary syndrome?
What percentage are discharged following rule out of NSTEMI and what is their length of stay?
How many people is the technology suitable for (consider selection criteria,
contraindications)?
Laboratory
Does the hospital laboratory have access to high-sensitivity troponin assays with the current
service contract in place?
Which manufacturer currently provides the biochemistry platforms? Do they offer NICE-
recommended high-sensitivity troponin assays?
When will the hospital laboratory be tendering for new equipment?
Care pathway mapping
What is the current care pathway? What actually happens? Where do people wait for troponin
results? Who is involved (decision making, doing tasks)?
What are the current follow-up care and onward referral arrangements?
What is the potential effect on other specialities, for example medical admissions and
cardiology, of adopting early rule-out protocols for NSTEMI using high-sensitivity troponin
assays?
Do we know of any other sites who have done this or are planning it? How do we learn from
them? Can we coordinate adoption with any local sites?
Cost
What are the anticipated costs and savings from adoption?
Is a business case needed and who is best placed to support this at a senior level and help
overcome any financial barriers?
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Measuring impact
What data do we currently collect for people presenting with chest pain suspected to be
caused by an acute coronary syndrome?
Who is currently responsible for collecting these data?
Step 3: Develop a communications strategy
There may be uncertainty among stakeholders about the diagnostic accuracy of ruling out NSTEMI
in a shorter time than before. There may also be concerns that using a higher-sensitivity cardiac
troponin assay will increase workload because of inappropriate testing and inaccurate
interpretation. It is important to share the potential benefits with stakeholders using methods
tailored approaches:
Depending on current local pathways, there could be fewer admissions for people with chest
pain suspected to be caused by an acute coronary syndrome who are waiting for troponin
results. It is estimated that following adoption, between a quarter and a third of people who
would have previously been admitted can be discharged.
There could be a shorter stay in the emergency department for people when an acute
myocardial infarction is ruled out.
There would be more appropriate referrals and onward follow up from the emergency
department to other services such as the rapid access chest pain clinic.
There would be more rapid identification of NSTEMI, leading to quicker decisions on the next
steps in the person's care.
There could be fewer referrals to cardiology from the emergency department for people with
chest pain suspected to be caused by an acute coronary syndrome. Note there may be an
increase in referrals for people who need further investigation and treatment.
Step 4: Procurement and set up of the preferred test
NICE has assessed 3 assays which measure cardiac troponin levels in the blood, to help the NHS
decide whether to use these products. The assays are called Elecsys Troponin T High Sensitive
(Roche Diagnostics), ARCHITECT STAT High Sensitive Troponin-I (Abbott Diagnostics) and
AccuTnI+3 (Beckman Coulter).
The Elecsys Troponin T High Sensitive and ARCHITECT STAT High Sensitive Troponin-I assays are
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recommended by NICE, alongside other investigations, to help doctors in emergency departments
work out whether people with chest pain thought to be caused by a heart problem are likely to be
having a heart attack or not. The AccuTnI+3 assay was only recommended for use in clinical
research, for early rule out of NSTEMI in people presenting to an emergency department with
chest pain and suspected acute coronary syndrome.
Roche Diagnostics - Elecsys Troponin T high-sensitive assay: is designed for use in a laboratory
setting and can be used on the Roche Elecsys 2010 analyser and the cobas Modular Analytics
e-series immunoassay analysers. The Elecsys test is a sandwich electrochemiluminescence
immunoassay, and is intended for the in vitro quantitative determination of troponin T in serum and
plasma samples. The Elecsys Troponin T high-sensitive assay has an estimated turnaround time of
18 minutes. The manufacturer states that the Elecsys assay can detect troponin T in 61% of the
reference population and has a recommended 99th percentile cut-off of 14 nanograms/litre, with a
coefficient of variation or imprecision of less than 10%. The assay is CE-marked and available to the
NHS.
Abbott Diagnostics - ARCHITECT STAT High Sensitive Troponin-I assay: is designed for use in a
laboratory setting and can be used with the Abbott ARCHITECT i2000SR and i1000SR analysers.
The assay is a chemiluminescent microparticle immunoassay and is intended for the in vitro
quantitative determination of cardiac troponin I in serum and plasma samples. Results are available
within 16 minutes. The manufacturer states that the ARCHITECT STAT High Sensitive Troponin-I
assay can detect troponin I in 96% of the reference population, and has a recommended 99th
percentile cut-off of 26.2 nanograms/litre, with a coefficient of variation of 4%. The manufacturer's
instructions for use also states a 99th percentile cut-off of 34.2 nanograms/litre for men and
15.6 nanograms/litre for women. The assay is CE-marked and available to the NHS.
The International Federation of Clinical Chemistry and Laboratory Medicine committee on clinical
applications of cardiac bio-markers has produced a high sensitivity cardiac troponin I and T assay
analytical characteristics document for all assays claimed by manufacturers to be high sensitivity.
Laboratories without access to high-sensitivity cardiac troponin assays through their managed
service contract should ask their provider if there is scope to access these tests. Some contracts
may state that when a test is clinically needed it can be sourced from another provider. Service
contracts are renewed regularly, therefore this could be a consideration in the tendering process
for a new contract.
Laboratories should adhere to their usual quality assurance and validation processes when
adopting high-sensitivity cardiac troponin assays in line with the UK accreditation service (UKAS),
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which includes checking if there are differences in results from all their platforms used to run the
high-sensitivity cardiac troponin assays.
Before adoption, laboratories should validate the assay at different values including the rule-out
cut off. This is particularly important because the sensitivity of the assay means that only small
changes influence clinical actions. Findings should be used to inform the cut-off values and
thresholds for developing the clinical protocol and give reassurance and confidence to stakeholders
about the benefits of adoption.
Both assays can be used for serum and plasma samples, but it is suggested that the same sample
type should be used when serially testing samples from the same patient. Ongoing internal quality
assurance will be required in line with UKAS. Sites should be signed up to a UKAS-accredited
external quality assessment scheme. Quality assurance checks should be done at or near clinical
decision points. This is commonly at the limit of detection and 99th percentile, as a minimum.
Sourcing internal quality assurance samples with a low concentration of troponin can be
challenging because producing such samples, at scale, can be technically difficult. Suggested
solutions include developing samples in house and identifying third-party providers who can offer
this. As with all internal quality assurance materials, sites will need to purchase the samples.
Because of the difficulty in getting low concentration samples this can be an additional cost for
some laboratories compared with other assays.
It is important for everyone involved to know which manufacturer's test is being used and the
specific pathway that is being followed, because the cut offs for the 2 assays are not
interchangeable.
Step 5: Agree an early rule-out clinical protocol
There is no nationally recommended protocol with thresholds and cut-off values for early rule out
of NSTEMI using high-sensitivity cardiac troponin assays in England. The NICE diagnostics
guidance on early rule out of NSTEMI using high-sensitivity troponin assays recommends a 2-test
strategy, typically on admission and at 3 hours. However, the committee concluded that there was
insufficient evidence to recommend a specific test strategy and agreed that early rule-out
protocols should be chosen according to local preference.
Sites should use relevant guidance including the European Society of Cardiology's guidelines on the
fourth universal definition of myocardial infarction, in addition to their own validation testing to
agree a local protocol. Considerations should include:
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Whether nanograms/litre will be used as the unit of measure for reporting, as recommended
by expert opinion.
Whether the upper reference limit should be set at the 99th percentile and if this will be used
to support decision making in the early rule-out pathway.
Whether the limit of detection will be used to support decision making in the pathway.
What evidence-based high-sensitivity cardiac troponin assay result is acceptable for discharge
(assuming there are no other reasons for admission).
What change in troponin values between the 2 tests should warrant further investigation or no
further action (a rise or fall in troponin levels can indicate cardiac muscle damage).
Whether results will be reported in whole numbers or to 1 decimal place. How this will affect
patient care if the result is near a threshold or a change in troponin is detected.
What risk stratification tools will be used and how the results will influence the high-sensitivity
cardiac troponin testing strategy.
How the time since pain onset will affect the testing strategy used.
Whether the protocol still allows and encourages clinical judgement (chest pain management
cannot be entirely protocol driven).
It is important to note that the limit of detection will vary between manufacturers. Also, the
99th percentile thresholds for troponin I and T will differ between manufacturers and may
differ between sexes.
Sites reported using a small implementation team or a specialist subgroup initially to develop and
agree a local protocol and then sought wider agreement from stakeholders.
If trusts can work together to agree a protocol across a locality or region this will make treatment
more consistent. The Liverpool acute chest pain care pathway is an example of this.
Step 6: Training
Staff training, education and awareness raising is crucial to ensure that the benefits of high-
sensitivity cardiac troponin assays for early rule out of NSTEMI are optimised. Education efforts
should target emergency department, acute medicine, cardiology and laboratory staff. Outreach
can take the form of presentations at team meetings, junior doctor inductions, study days, training
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sessions, and targeted emailing to staff.
Training at the point of implementation and regular ongoing updates should include:
Patient selection: The person responsible for deciding who the test should be requested for
should be skilled in patient selection to minimise the risk of inappropriate requests.
Blood-taking techniques: Haemolysed samples give false high-sensitivity cardiac troponin
results. This could cause delays. Blood collection tube manufacturers may be able to support
this training.
Interpretation: High-sensitivity cardiac troponin results are interpreted differently from non-
high-sensitivity cardiac troponin results. They should not be interpreted and acted on in
isolation but after a holistic clinical assessment.
Step 7: Adoption into practice
To realise the benefits of using high-sensitivity cardiac troponin assays for early rule out of
NSTEMI, sites will need a change in service delivery to integrate the early rule-out protocol into
current hospital systems. Consider:
Whether any new documentation is needed (protocols, flow charts, referral forms).
Identifying who will be responsible for requesting the high-sensitivity cardiac troponin assay.
Usually this is the emergency department and acute medicine doctors and nurse practitioners.
Ensuring the assays are done only when appropriate.
Ensuring the initial blood sample is taken as soon as the protocol indicates.
Ensuring there is capacity for people to wait in an appropriate allocated location for the results
and for a second blood sample to be taken, ideally avoiding a formal admission to the hospital.
Can an ambulatory care environment be used with chairs rather than beds?
Ensuring the second sample is taken as soon as it is due to prevent delays. This may be before
the initial test results are available. Clear documentation and handover sheets can help.
Putting a system in place to ensure that relevant staff are aware of a result as soon as it is
available. Delays at this stage are common.
Agreeing who will be responsible for decision making based on the results. This is usually
senior doctors in the emergency department, cardiology or acute medicine. Some sites have
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recruited chest pain nurses who advise the emergency department on interpreting troponin
results in complex situations.
Identifying how the testing protocol will affect patient flow and workload.
Establishing discharge and onward referral arrangements, which could include:
when nurse-led discharge protocols could be used
acute chest pain referral pathways to acute medicine for patients who meet certain
criteria
clear agreements with cardiology, including nurse specialists, about when to review
patients if they meet certain criteria
adaptation of the referral pathway for rapid access chest pain clinics to take patients
who meet defined criteria.
Developing discharge information sheets for patients and their GPs, or ensuring enough
information is added to the emergency department GP discharge letter, to clarify what tests
have been done and what they mean. This could prevent workload associated with follow-up
enquiries.
Identifying any changes needed in laboratory processes to achieve a turnaround time from the
sample arriving in the laboratory to a result at 1 hour.
Step 8: Measurement
It is important to take measurements before, during and after adopting the technology to ensure
implementation has been successful. The systems and processes for how data will be collected and
reported must be agreed and someone given overall responsibility. Consider whether the data
could be shared with regional and national data collection systems to support ongoing refinement
of protocols.
Monitoring performance
These audit measures are suggested to monitor compliance with using local early rule out of
NSTEMI protocols with high-sensitivity troponin assays:
High-sensitivity cardiac troponin assays are done in line with the local protocol.
Patients on a pathway for early rule out of NSTEMI are assessed for their risk of myocardial
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© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-
conditions#notice-of-rights).
Page 14 of
28
infarction (as indicated by a validated tool).
Patients have a sample taken to measure troponin within a locally agreed time period, in line
with the timings recommended by the protocol.
Turnaround times in the laboratory from sample receipt (or sample collection if agreed locally)
to availability of the result within 1 hour. This is in line with suggested key performance
indicators from the Royal College of Pathologists linked to patient pathways and emergency
department blood sciences turnaround times.
Measuring impact
There are several suggested measures which could assess impact:
For people with chest pain suspected to be caused by an acute coronary syndrome, time spent
in the emergency department.
Transit times for people going through the emergency department on the acute coronary
syndrome rule out pathway.
Incidence of readmission of people with troponin-positive acute coronary syndrome within
30 days following the low-risk rule-out pathway.
Admission rates for chest pain suspected to be caused by an acute coronary syndrome
(suggested ICD10 code: R07) when the early rule-out protocol is in place.
Adoption support resource – insights from the NHS
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Potential barriers to implementation and mitigating action
Table 1 summarises the key barriers to adoption gathered from the experiences and learning of
contributors to this resource.
Table 1 Summary of the key barriers to adoption
Challenge Suggested actions
Access to a recommended high-
sensitivity troponin assay
Clinical biochemistry departments:
actively engage with emergency departments to share
the benefits of high-sensitivity troponin assays if these
are available
explore how to source recommended high-sensitivity
troponin assays if these are not available. Check contracts
for allowances for new tests when there is a clinical need
include the benefits of high-sensitivity troponin assays
when tendering for service contracts.
Agreement between
emergency department,
cardiology, clinical biochemistry
and acute medicine about the
most appropriate early rule-out
protocol
Identify a clinical champion with an interest in using high-
sensitivity troponin assays for early rule out of
non-ST-segment-elevation myocardial infarction
(NSTEMI), to engage colleagues in adoption.
Form a specialised implementation team to draft the early
rule-out protocol. This will be a small group of senior
representatives from the emergency department,
cardiology, clinical biochemistry and acute medicine.
Use information from local validation testing of the assay
and protocol to secure support from stakeholders.
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Inappropriate testing reduces
clinical confidence in the test
Use clear protocols defining which patients' high-
sensitivity troponin assays should be used for the early
rule out of NSTEMI.
Organise ongoing training and updates for staff
responsible for ordering the test and record training.
Regularly audit practice against local guidance on who
the assay should be requested for.
Allocation of resources
Work with trust finance staff to support any necessary
business cases and redistribution of resources when
needed.
Factor into finance planning that anticipated savings will
be seen in emergency department, cardiology and acute
medicine through quicker discharge. Costs are likely to be
incurred by the laboratory for the assay and consumables
and staff costs for the quality assurance work.
Measuring the impact of
adoption
During adoption planning, identify the measures of
success and agree who will be responsible for collecting
and reporting this information. Agree how the
information will be used.
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Resources
Table 2 details resources that could be used to support the case for adoption locally.
Table 2 List of resources
Resource How this could support the case for adoption
locally
NICE's guideline on chest pain of recent onset Section 1.2.5: Use of biochemical markers for
diagnosis of an acute coronary syndrome.
National guidance provides assurance of the
evidence base supporting the change in
practice.
NICE's diagnostics guidance on myocardial
infarction (acute): early rule out using high-
sensitivity troponin tests
National guidance provides assurance of the
evidence base supporting the change in
practice.
European Society of Cardiology (2015)
guidelines on acute coronary syndromes in
patients presenting without persistent ST-
segment elevation
International guidance provides assurance of
the evidence base supporting the change in
practice.
The association for clinical biochemistry and
laboratory medicine (2019) national audit
Indicates current practice and allows
benchmarking.
The clinical audit tool for NICE's diagnostics
guidance on myocardial infarction (acute): early
rule out using high-sensitivity troponin tests
Tool to collect information on the time taken
to rule out non-ST-segment-elevation
myocardial infarction (NSTEMI) in clinical
practice and on the clinical outcomes of
people presenting to an emergency
department with chest pain and suspected
acute coronary syndrome.
International Federation of Clinical Chemistry
and Laboratory Medicine's resources from the
committee on clinical applications of cardiac
biomarkers
Online resources and publications to support
adoption of high-quality testing locally.
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Hospital episodes statistics (HES) data for
accident and emergency activity
Provides high-level data including the
number of patients admitted for cardiac
conditions. More detailed data would need
HES data extraction.
NHS England's A&E attendances and
emergency admissions
Includes data on the number of patients
discharged, admitted or transferred within
4 hours of arrival. Could be used locally to
identify a need to reduce emergency
department waiting times.
Januzzi JL et al. (2019) Recommendations for
Institutions Transitioning to High-Sensitivity
Troponin Testing. Journal of the American
College of Cardiology 73 (9): 1059–77
Provides prompts for sites to consider when
planning adoption of an early rule-out
protocol.
AHSN/Peninsula Collaboration for Health
Operational Research and Development
(PenCHORD) project – Cardiac troponin:
diagnosing heart attacks in A&E
This project and associated report explores
the potential impact on heart attack care
pathways in the South West, if high-
sensitivity troponin assays are implemented
consistently. The content could be used for
developing business cases locally and
planning adoption.
Ambavane A et al. (2017) Economic evaluation
of the one-hour rule-out and rule-in algorithm
for acute myocardial infarction using the high-
sensitivity cardiac troponin T assay in the
emergency department. PLOS ONE 12(11):
e0187662
May help support the development of a
business case locally.
NHS England Innovation and Technology
Payment (ITP) 2019/20 – High sensitivity
troponin assay in a rapid rule out protocol for
acute myocardial infarction
Website information and technical notes can
be used in developing a business case and
planning adoption to ensure ITP payments
are directed locally.
Thygesen K, Alpert JS, Jaffe AS et al. (2019)
Fourth universal definition of myocardial
infarction (2018) European Heart Journal 40
(3): 237–269
Provides information and details about
diagnosing myocardial infarction, which will
be useful to teams developing clinical
protocols.
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Wu AHB, Christenson RH, Greene DN et al.
(2018) Clinical Laboratory Practice
Recommendations for the Use of Cardiac
Troponin in Acute Coronary Syndrome: Expert
Opinion from the Academy of the American
Association for Clinical Chemistry and the Task
Force on Clinical Applications of Cardiac Bio-
Markers of the International Federation of
Clinical Chemistry and Laboratory Medicine.
Clinical Chemistry 64 (4): 645–655
Focuses on clinical laboratory practice
recommendations for high-sensitivity
troponin assays.
Risk scores:
Emergency Department Assessment of Chest
Pain score (EDACS)
GRACE score
GRACE 2
HEART score
TIMI risk score
T-MACS
These are not being presented as validated
or approved tools. These are scoring systems
contributors referred to during the
development of this resource. Users should
be aware of the risks and benefits of each
tool as a prognostic stratification tool, to
understand how the result can be used in
clinical practice. The choice of tool should be
considered in the context of the high-
sensitivity troponin assay in use.
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Clinical pathway and algorithms
Here are some examples of protocols and pathways developed by NHS services that can be used
for developing local documents. They have been shared by contributors; they were not produced
for, or commissioned by, NICE. These protocols were in use at the trust at the time of publication,
however sites are reviewing and updating these on an ongoing basis.
Aintree University Hospital NHS Foundation Trust: Liverpool acute chest pain care pathway
North Bristol NHS Trust: Suspected acute coronary syndrome guideline
Gloucestershire Hospitals NHS Foundation Trust: Cardiac chest pain pathway
Adoption support resource – insights from the NHS
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Implementation
Table 3 is a suggested implementation checklist which can be used locally to help guide the project
team through the adoption process.
Table 3 Implementation checklist
Element Checklist
Project start Project leads identified:
clinical project champion
project lead or manager
project or management sponsor who will be able to help assess the
financial viability of the project, ensure a business case is produced and
help to show the potential cost savings.
Key stakeholders identified:
cardiologists
chest pain nurse specialists
emergency department doctors and senior nurses
doctors from the acute medical team
clinical biochemists.
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Other internal stakeholders identified:
pharmacists
healthcare professionals working in the emergency department, acute
medical units, cardiology and hospital laboratories
operational and finance management
clinical directors
commissioners.
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Assess
readiness
Current demand
How many people present to the emergency department with chest pain
suspected to be caused by an acute coronary syndrome?
What percentage are discharged following rule out of
non-ST-segment-elevation myocardial infarction (NSTEMI) and what is
their length of stay?
How many people is the technology suitable for (consider selection
criteria, contraindications)?
Laboratory
Does the hospital laboratory have access to high-sensitivity troponin
assays with the current service contract in place?
Which manufacturer currently provides the biochemistry platforms? Do
they offer NICE-recommended high-sensitivity troponin assays?
When will the hospital laboratory be tendering for new equipment?
Care pathway mapping
What is the current care pathway? What actually happens? Where do
people wait for troponin results? Who is involved (decision making, doing
tasks)?
What are the current follow-up care and onward referral arrangements?
What is the potential effect on other specialities, for example medical
admissions and cardiology, of adopting early rule-out protocols for
NSTEMI using high-sensitivity troponin assays?
Do we know of any other sites who have done this or are planning it?
How do we learn from them? Can we coordinate adoption with any local
sites?
Cost
What are the anticipated costs and savings from adoption?
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Is a business case needed and who is best placed to support this at a
senior level and help overcome any financial barriers?
Measuring impact
What data do we currently collect for people presenting with chest pain
suspected to be caused by an acute coronary syndrome?
Who is currently responsible for collecting these data?
Agreement to
proceed
Business case developed and submitted?
Agreement to proceed based on value proposition?
Developing
communications
plans
Internal stakeholders engaged?
External stakeholders engaged?
Identify
preferred assay
Engagement with manufacturers?
Service contracts discussed?
Assay validation checks completed?
Engaged with UKAS accredited external quality assurance service and
internal and external quality assurance programme agreed?
Quality assurance samples for (internal quality assurance) containing low
levels of troponin sourced?
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Agree clinical
pathway
Timings of troponin tests agreed?
Cut-off thresholds and delta changes agreed?
Risk scoring tool to support decision making selected?
Criteria for onward referrals agreed?
Pathway agreed across a region or locality?
Roll out training
Champion responsible for ensuring training for relevant staff groups?
Trainers identified?
Spread of training monitored?
Adoption into
practice
Staff groups with responsibility for requesting high-sensitivity troponin
assays identified?
Staff groups with responsibility for acting on high-sensitivity troponin
assay results identified?
Strategies adopted to ensure blood tests are taken as soon as the
protocol indicates?
Suitable location agreed for patients to wait for tests and results?
Discharge and onward referral protocols or criteria agreed?
Monitor
performance
Audit lead identified?
Audit standards and audit plan written?
Measure impact
Agreement of service level measures to show impact on practice?
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